鼻腔给药
CD44细胞
透明质酸
化学
医学
癌症研究
胶质瘤
细胞穿透肽
细胞毒性
体内
黑色素瘤
血脑屏障
体外
药理学
小干扰RNA
细胞
中枢神经系统
生物
内科学
转染
生物化学
解剖
生物技术
基因
作者
Yuling Yang,Xueyan Zhang,Siwen Wu,Rui Zhang,Bailing Zhou,Xiaoyu Zhang,Lin Tang,Yaomei Tian,Ke Men,Li Yang
标识
DOI:10.1016/j.jconrel.2021.12.034
摘要
Gliomas are the most malignant brain tumors, and their treatment is very challenging because of the presence of the blood-brain barrier (BBB). Intranasal administration has been considered a noninvasive strategy for glioma therapy in recent years, but our explorations of the intranasal delivery of siRNA-based therapies are still clearly inadequate. In this study, the cell-penetrating peptide DP7-C was enveloped with hyaluronic acid (HA) to develop the multifunctional core-shell structure nanomicelle HA/DP7-C. In vitro studies of HA/DP7-C revealed low cytotoxicity and a higher cell uptake efficiency, which was associated with the interaction between HA and CD44. In vivo experiments indicated that HA/DP7-C delivered the siRNA to the central nervous system through the trigeminal nerve pathway within hours after intranasal administration and that the interaction between HA and CD44 also increased its accumulation at the tumor site. Successful intracellular delivery of an antiglioma siRNA inhibited tumor growth and ultimately prolonged the survival time and decreased the tumor volume in GL261 tumor-bearing mice. In addition, toxicity tests on rats showed no adverse effects on the nasal mucosa and trigeminal nerves. In conclusion, HA/DP7-C is a potential intranasal delivery system for siRNAs in glioma therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI